Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Not Yet Opened 08-11 16:00:00 EDT

8.51

-0.06

-0.70%

盘后8.46

-0.05-0.58%

19:34 EDT

High8.82	Low8.47	Vol1.79M
Open8.61	D1 Closing8.57	Amplitude4.14%
Mkt Cap688.47M	Tradable Cap544.01M	Total Shares80.90M
T/O15.41M	T/O Rate2.80%	Tradable Shares63.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":8.51,"timestamp":1786478400000,"preClose":8.57,"halted":0,"volume":1787260,"hourTrading":{"tag":"盘后","latestPrice":8.4607,"preClose":8.51,"latestTime":"19:34 EDT","volume":13301,"amount":113151.7605,"timestamp":1786491248209,"change":-0.0493,"changeRate":-0.005793,"amplitude":0.005793},"delay":0,"changeRate":-0.007001166861143581,"floatShares":63926354,"shares":80900900,"eps":-1.265918,"marketStatus":"Not Yet Opened","change":-0.06,"latestTime":"08-11 16:00:00 EDT","open":8.61,"high":8.82,"low":8.465,"amount":15409737.8474,"amplitude":0.041424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.265918,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786521600000},"marketStatusCode":0,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":8.57,"preHourTrading":{"tag":"盘前","latestPrice":8.79,"preClose":8.57,"latestTime":"08:08 EDT","volume":6,"amount":52.32999600000001,"timestamp":1786450134470,"change":0.22,"changeRate":0.025671,"amplitude":0.016336},"postHourTrading":{"tag":"盘后","latestPrice":8.4607,"preClose":8.51,"latestTime":"19:34 EDT","volume":13301,"amount":113151.7605,"timestamp":1786491248209,"change":-0.0493,"changeRate":-0.005793,"amplitude":0.005793},"volumeRatio":0.914545,"impliedVol":2.3158,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/PHAT/wiki","defaultTab":"wiki","newsList":[{"id":"2656392923","title":"Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough","url":"https://stock-news.laohu8.com/highlight/detail?id=2656392923","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656392923?lang=en_us&edition=fundamental","pubTime":"2026-08-01 07:28","pubTimestamp":1785540515,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals came into this earnings print with a bruised stock chart, down double digits over the past month and quarter, and it slipped another 3.1% to US$8.75 in the first full trading day after results. The headline, however, is not the share price. The company reported its first quarter of operating profit on a cash basis excluding stock based compensation, on revenue of US$74.3m.\nFor a gastrointestinal focused biotech that has been firmly in loss making territory, that shift...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/phathom-pharmaceuticals-phat-stock-slides-despite-cash-profi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/phathom-pharmaceuticals-phat-stock-slides-despite-cash-profi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4588","SPHQ","PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655281388","title":"Phathom Pharmaceuticals is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2655281388","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655281388?lang=en_us&edition=fundamental","pubTime":"2026-07-31 03:35","pubTimestamp":1785440100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655886383","title":"Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2655886383","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655886383?lang=en_us&edition=fundamental","pubTime":"2026-07-31 03:20","pubTimestamp":1785439238,"startTime":"0","endTime":"0","summary":"Needham lowered the firm’s price target on Phathom Pharmaceuticals (PHAT) to $22 from $28 and keeps a Buy rating on the shares. The company reporte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-price-target-lowered-to-22-from-28-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-price-target-lowered-to-22-from-28-at-needham-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804247","title":"Phathom Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804247","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804247?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:38","pubTimestamp":1785429494,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryPhathom Pharmaceuticals IncPHAT.OQreported a quarterly adjusted loss of 21 cents per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL8N43W39F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655804205","title":"Phathom Pharmaceuticals Down over 19%, on Track for Largest Percent Decrease Since May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2655804205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655804205?lang=en_us&edition=fundamental","pubTime":"2026-07-31 00:32","pubTimestamp":1785429120,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc.  is currently at $9.34, down $2.30 or 19.76%--Would be lowest close since June 1, 2026, when it closed at $9.24--On pace for largest percent decrease since May 1, 2025, when it fell 21.68%--Currently down five of the past six days--Currently down three consecutive days; down 21.84% over this period--Worst three day stretch since the three days ending May 6, 2025, when it fell 28.57%--Down 13.92% month-to-date; on pace for worst month since May 2026, when it fell 14.37%--Down 43.7% year-to-date--Down 82.89% from its all-time closing high of $54.60 on June 8, 2020--Up 9.37% from 52 weeks ago , when it closed at $8.54--Down 48.34% from its 52-week closing high of $18.08 on Jan. 7, 2026--Up 11.86% from its 52-week closing low of $8.35 on Aug. 1, 2025--Traded as low as $8.90; lowest intraday level since June 2, 2026, when it hit $8.78--Down 23.54% at today's intraday low; largest intraday percent decrease since May 1, 2025, when it fell as much as 28.44%All dat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655987926","title":"Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2655987926","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655987926?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:18","pubTimestamp":1785410307,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growthOverviewUS biopharma firm's Q2 revenue rose 88% yr/yr, beating analyst expectationsQ2 operating expenses fell 33% yr/yr due to l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4007","BK4532","IE00B894F039.SGD","BK4585","LU0320765992.SGD","BK4588","PSCH","BK4533","PBE","BMED","BK4139","LU0566484027.USD","CORT","FBT","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","BIIB","LU0109394709.USD","PHAT","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655287645","title":"Phathom Q2 GAAP Net Loss Narrows to $17.6 Million from Year-ago; Revenue Rises 88% to $74.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655287645","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655287645?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:01","pubTimestamp":1785409265,"startTime":"0","endTime":"0","summary":"Phathom Q2 GAAP net loss narrows to $17.6 million from year-ago; revenue rises 88% to $74.3 millionPhathom reported Q2 2026 net revenues of $74.3 million, up 88% from Q2 2025 and 27% from Q1 2026.Net ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL8gRNRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BCDF","IE00BN0W2T93.GBP","BK4007","LU2210150020.SGD","PHAT","SG9999014005.SGD","BK4585","SG9999014021.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655087612","title":"Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2655087612","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655087612?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:00","pubTimestamp":1785409239,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent.  This is a 88.09 percent increase over sales of $39.503","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60792413/phathom-pharmaceuticals-q2-sales-74-300m-beat-72-789m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655887635","title":"Phathom Pharmaceuticals Outlook FY Revenue USD 310-325 Million VS. Ibes Estimate USD 332.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655887635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655887635?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:59","pubTimestamp":1785409141,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXZ7BFFR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655587638","title":"Phathom Pharmaceuticals Q2 Net Income USD -17.582 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655587638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655587638?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:59","pubTimestamp":1785409141,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nPLXZ7BFFR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655871909","title":"Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2655871909","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655871909?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:59","pubTimestamp":1785409140,"startTime":"0","endTime":"0","summary":"~1.7 million total VOQUEZNA prescriptions filled to dateRecord Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026Q2 operating expenses of $63.1 million, reduced by 33","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335890/0/en/Phathom-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1721429741.USD","IE00BN0W2T93.GBP","LU2089279066.USD","IE00BN0W2V16.EUR","LU0347712357.USD","BK4588","BK4121","A","LU2413666699.HKD","LU2041044095.USD","BK4585","LU2413666426.HKD","LU1543694498.USD","LU1721428933.USD","BK4567","LU1721429402.USD","LU2229751404.USD","PHAT","PRN","BK4007","LU2092937221.SGD","LU1165135440.EUR","NERD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213837","title":"Phathom Pharma Schedules Second-quarter Earnings Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652213837?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:02","pubTimestamp":1784548962,"startTime":"0","endTime":"0","summary":"Phathom Pharma schedules second-quarter earnings webcastPhathom Pharmaceuticals will report second-quarter 2026 results on July 30, 2026.A business update will accompany the 8:00 a.m. EDT webcast on J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL6BHVpy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","PHAT","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4585","BK4112","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588","BCDF","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","LU0314104364.USD","SG9999014013.SGD","BK4007","IE00BGHQF748.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213805","title":"Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213805","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652213805?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:00","pubTimestamp":1784548800,"startTime":"0","endTime":"0","summary":"Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDTFLORHAM PARK, N.J., July  20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3329653/0/en/Phathom-Pharmaceuticals-to-Report-Second-Quarter-2026-Financial-Results-and-Provide-Business-Update-on-Thursday-July-30-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646846919","title":"Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646846919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646846919?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:40","pubTimestamp":1782333620,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX). Ph...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-phathom-pharmaceuticals-phat-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-phathom-pharmaceuticals-phat-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","HCSG","LU0029874061.USD","BK4588","XBI","LABU","ELTX","PHAT","BK4139","XLV","LU0128526141.USD","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645392418","title":"Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645392418","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645392418?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:51","pubTimestamp":1782219090,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating Voquezna tablets as a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-completes-enrollment-in-phalcon-eoe-201-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-completes-enrollment-in-phalcon-eoe-201-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645369738","title":"Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna","url":"https://stock-news.laohu8.com/highlight/detail?id=2645369738","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645369738?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:26","pubTimestamp":1782217604,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals  said Tuesday it has completed the enrollment in its phase 2 clinical trial evaluating Voquezna, or vonoprazan, as a potential treatment for eosinophilic esophagitis, a chronic inflammatory disease of the esophagus.The study enrolled 95 adult patients across 41 US clinical sites and is assessing the drug as a non-steroidal oral therapy. Topline results are expected in Q4, the company said.Phathom said the trial could help determine whether its acid suppression therapy offers a new treatment approach for patients who currently rely on proton pump inhibitors, which are not approved for the condition.If the results are positive, the company said it plans to engage with US regulators on further development, including potential pediatric studies and broader indications.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835120","title":"Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835120?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215960,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals completed enrollment in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA  in adult eosinophilic esophagitis.Topline results for the 12-week double-blind portion are expected in Q4 2026; results have not been presented yet.The placebo-controlled study is designed to assess whether vonoprazan can improve swallowing-related symptoms and disease activity versus placebo.A positive readout could support talks with the FDA on next development steps in EoE, including potential pediatric evaluation.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL8slZgR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2W23.USD","LU0314104364.USD","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","SG9999014013.SGD","BK4007","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835992","title":"Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835992?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA2YQXL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835918","title":"Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835918?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA2YQXL3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836848","title":"Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836848","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836848?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215940,"startTime":"0","endTime":"0","summary":"This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4 o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/23/3315866/0/en/Phathom-Pharmaceuticals-Completes-Patient-Enrollment-Ahead-of-Schedule-in-Phase-2-pHalcon-EoE-201-Study-of-VOQUEZNA-vonoprazan-in-Eosinophilic-Esophagitis-EoE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","BK4007","PHAT","BK4570","PPI","TEN","BK4144"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":-0.3251},{"period":"3month","weight":-0.3225},{"period":"6month","weight":-0.292},{"period":"1year","weight":-0.1722},{"period":"ytd","weight":-0.487}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0207},{"period":"3month","weight":0.0381},{"period":"6month","weight":0.1311},{"period":"1year","weight":0.2117},{"period":"ytd","weight":0.13}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.079508},{"month":2,"riseRate":0.571429,"avgChangeRate":0.0658},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.119249},{"month":4,"riseRate":0.571429,"avgChangeRate":0.046876},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.041373},{"month":6,"riseRate":0.714286,"avgChangeRate":0.230291},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.006164},{"month":8,"riseRate":0.571429,"avgChangeRate":0.126247},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003613},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.040055},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.100392},{"month":12,"riseRate":0.714286,"avgChangeRate":0.070942}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}